U.S. FDA approves Reata’s rare genetic disorder drug
Feb 28 (Reuters) - The US Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc's Skyclarys drug to treat a rare genetic disorder that causes progressive damage to the nervous system.
Reata estimates that…